We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

36 hedge funds and large institutions have $104M invested in CERo Therapeutics in 2021 Q4 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% more ownership

Funds ownership: 0% → 0.03% (+0.03%)

Holders
36
Holders Change
+36
Holders Change %
–
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
36
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
Beryl Capital Management
California
+$12.2M
2
HCM
Highbridge Capital Management
New York
+$10.3M
3
Citadel Advisors
Citadel Advisors
Florida
+$7.44M
4
SCM
Saba Capital Management
New York
+$6.35M
5
Marshall Wace
Marshall Wace
United Kingdom
+$6.23M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
26
Rivernorth Capital Management
Florida
$496K +$496K +25 New
WA
27
Whitebox Advisors
Minnesota
$496K +$496K +25 New
TI
28
Telemetry Investments
New York
$304K +$298K +15 New
DCM
29
Dupont Capital Management
Delaware
$248K +$258K +13 New
WP
30
Woodline Partners
California
$248K +$258K +13 New
SV
31
Starboard Value
New York
$238K +$238K +12 New
DFCM
32
Dark Forest Capital Management
Puerto Rico
$208K +$199K +10 New
HF
33
HRT Financial
New York
$137K +$139K +7 New
DAM
34
Deltec Asset Management
New York
$99K +$99.3K +5 New
SCM
35
Segantii Capital Management
Hong Kong
$99K +$99.3K +5 New
PCM
36
Pinz Capital Management
New York
$72K +$79.4K +4 New
1
2

CERO Hedge Fund Activity: Q4 2021 in Review

36 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q4 2021, worth a combined $104M.

Buyers outnumbered sellers: 36 funds opened new CERO positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Beryl Capital Management, opening a new position worth an estimated $12.2M.

  • 36 institutional investors held CERo Therapeutics (CERO) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $104M of CERo Therapeutics stock for Q4 2021.
  • 36 funds opened new CERo Therapeutics positions in Q4 2021 and 0 closed out, a net change of +36 holders.
  • The largest CERo Therapeutics buyer in Q4 2021 was Beryl Capital Management, an estimated $12.2M added.

Based on aggregated 13F filings for Q4 2021.